Abstract | Purpose: Methods: Conventional electroretinograms (ERGs) and dark-adapted 10-Hz flicker ERGs were recorded in control and Rs1 -/Y mice generated with CRISPR/Cas9. ON-pathway blocker 2-amino-4-phosphobutyric acid (APB) was injected intravitreally. Morphology was evaluated with histology and optical coherence tomography (OCT). Mice were treated with a CAI inhibitor brinzolamide eye drops (10 mg/ml) three times a day for 3 months. OCT and ERG findings at 1, 4, and 10 months were analyzed. Results: Negative ERGs and retinal cavities were evident in Rs1 -/Y mice. Both a-wave and b-wave amplitudes decreased with age when compared with age-matched controls. The APB-isolated a-wave (a') amplitudes of Rs1 -/Y mice were reduced in all age groups. In dark-adapted 10-Hz flicker ERG, the amplitude-intensity curve of Rs1 -/Y mice shifted down. The thickness of ONL and IS/OS decreased in Rs1 -/Y mice. CAI reduced the splitting retinal cavities but didn't affect the ERG. Conclusions: In addition to post receptoral impairments, photoreceptor cells underwent progressive dysfunction since early age in Rs1 -/Y mice. Long-term CAI treatment improved the shrinkage of the splitting retinal cavity, while no functional improvement was observed.
|
Authors | Meng Liu, Jingyang Liu, Weiping Wang, Guangming Liu, Xiuxiu Jin, Bo Lei |
Journal | Frontiers in medicine
(Front Med (Lausanne))
Vol. 9
Pg. 886947
( 2022)
ISSN: 2296-858X [Print] Switzerland |
PMID | 35836954
(Publication Type: Journal Article)
|
Copyright | Copyright © 2022 Liu, Liu, Wang, Liu, Jin and Lei. |